MBX vs MLYS: fair value comparison
MBX Biosciences, Inc. and Mineralys Therapeutics, Inc. · Updated 2026-10-19
MBX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. MLYS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MBX currently ranks higher by quality score.
| MBX | MLYS | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $49.61 | $20.30 |
| 12-month range | $16.13–$70.70 | $20.30–$47.33 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #250 of 301 Healthcare | #252 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: MBX fair value analysis · MLYS fair value analysis